Adaptimmune Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Adaptimmune Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-16.4%
Buyback Yield
| Total Shareholder Yield | -16.4% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ADAP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADAP's dividend payments have been increasing.
Dividend Yield vs Market
| Adaptimmune Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ADAP) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (ADAP) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ADAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ADAP's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ADAP has not reported any payouts.